[Vasoactive drugs in peripheral arterial perfusion disorders. Problems, principles and results of the determination of therapeutic efficacy].
D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002936:Cinnarizine / Q000031:analogs & derivatives / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004087:Dihydroergotamine / Q000627:therapeutic use; D004088:Dihydroergotoxine / Q000627:therapeutic use; D004338:Drug Combinations; D005080:Exercise Test; D005444:Flunarizine; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy; D009257:Nafronyl / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D010919:Placebos; D011759:Pyrrolidines / Q000627:therapeutic use; D046948:Secologanin Tryptamine Alkaloids; D015016:Yohimbine / Q000627:therapeutic use
D002317:Cardiovascular Agents; D004338:Drug Combinations; D010919:Placebos; D011759:Pyrrolidines; D046948:Secologanin Tryptamine Alkaloids; D004088:Dihydroergotoxine; D015016:Yohimbine; D002936:Cinnarizine; D009257:Nafronyl; D004087:Dihydroergotamine; C005709:raubasine; D005444:Flunarizine; D010431:Pentoxifylline; C010651:buflomedil
Vasoaktive Pharmaka bei peripheren arteriellen Durchblutungsstörungen. Probleme, Prinzipien und Ergebnisse des therapeutischen Wirksamkeitsnachweises.